Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China

References

• Hinman AR, Orenstein WA, Schuchat A. Centers for disease, control prevention. Vaccine-preventable diseases, immunizations, and MMWR: 1961–2011. MMWR Surveill Summ. 2011;60:49–7.
   Google Scholar
• De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol. 2000;151(11):1039–48. doi:10.1093/oxfordjournals.aje.a010145.
   PubMed Web of Science ®Google Scholar
• Arístegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7(2):143–51. doi:10.1016/S1201-9712(03)90011-7.
   PubMedGoogle Scholar
• Zhang L, Wilson DP. Trends in notifiable infectious diseases in China: implications for surveillance and population health policy. PLoS One. 2012;7(2):e31076. doi:10.1371/journal.pone.0031076.
   PubMed Web of Science ®Google Scholar
• Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016;34(12):1436–43. doi:10.1016/j.vaccine.2016.02.010.
   PubMed Web of Science ®Google Scholar
• Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374(9693):903–11. doi:10.1016/S0140-6736(09)61203-4.
   PubMed Web of Science ®Google Scholar
• WHO Global Programme for Vaccines and Immunization. The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiol Record 1998;73:64–68.
   PubMedGoogle Scholar
• Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72. doi:10.4103/0974-777X.77298.
   PubMedGoogle Scholar
• Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM. Taiwan Infanrix-069 Study G. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants. J Formos Med Assoc. 2011;110:415–22. doi:10.1016/S0929-6646(11)60061-2.
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Contreras-Roldan IL, Ram M, Garcia-Melgar AJ, Morales-Oquendo V, Hartman K, Rauscher M, Moulton LH, Halsey NA. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31(49):5909–14. doi:10.1016/j.vaccine.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Anh DD, Van Der Meeren O, Karkada N, Assudani D, Yu TW, Han HH. Safety and reactogenicity of the combined diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: an open-label, phase III study. Hum Vaccin Immunother. 2016;12:655–57. doi:10.1080/21645515.2015.1084451.
   PubMed Web of Science ®Google Scholar
• Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Ann Acad Med Singapore. 2008;37:546–53.
   PubMed Web of Science ®Google Scholar
• Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccin Immunother. 2021;17(10):3823–30. doi:10.1080/21645515.2021.1939621.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–46. doi:10.1016/j.vaccine.2015.04.060.
   PubMed Web of Science ®Google Scholar
• Rust J. Updating the international classification of diseases and related health problems, tenth revision (ICD-10). Health Info Manage J Health Inf Manage Assoc Aus. 2010;39(2):40. doi:10.1177/183335831003900207.
   PubMedGoogle Scholar
• Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 To 2011 in Zhejiang Province, China. Clin Vaccine Immunol CVI. 2013;20:211–17.
   PubMedGoogle Scholar
• Hu Y, Chen Y. Evaluating childhood vaccination coverage of NIP vaccines: coverage survey versus Zhejiang Provincial immunization information system. Int J Environ Res Public Health. 2017;14: 758 .
   Web of Science ®Google Scholar
• Kim S, Park K, Kim MS, Yang BR, Choi HJ, Park BJ. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Res. 2017;256:237–42. doi:10.1016/j.psychres.2017.06.038.
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, Von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12. doi:10.1097/01.inf.0000222413.47344.23.
   PubMed Web of Science ®Google Scholar
• David S, Bondt PE V-D, Van Der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. Vaccine. 2008;26(46):5883–87. doi:10.1016/j.vaccine.2008.07.105.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/Haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/Haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–20. doi:10.1016/j.vaccine.2010.08.062.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang H, Zhou W, Ye Q, Li F, Wang H, Hou Q, Xu Y, Ma X, Tan Y, et al. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. Vaccine. 2010;28(25):4215–23. doi:10.1016/j.vaccine.2010.03.061.
   PubMed Web of Science ®Google Scholar
• White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines. 2009;8(7):831–40. doi:10.1586/erv.09.59.
   PubMed Web of Science ®Google Scholar
• Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines. 2005;4(6):793–805. doi:10.1586/14760584.4.6.793.
   PubMed Web of Science ®Google Scholar
• Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Data System Rev. 2009;3:Cd005530.
   Google Scholar
• Tomianovic D, Bauwens J, Heininger U, Bonhoeffer J. Global vaccine safety assessment: challenges and opportunities. Pediatr Infect Dis J. 2016;35(4):446–48. doi:10.1097/INF.0000000000000983.
   PubMed Web of Science ®Google Scholar
• Yoon D, Kim JH, Lee H, Shin JY. Updates on vaccine safety and post-licensure surveillance for adverse events following immunization in South Korea, 2005-2017. Yonsei Med J. 2020;61:623–30.
   PubMed Web of Science ®Google Scholar
• Oliveira PMN, Lignani LK, Conceicao DAD, Farias P, Takey PRG, Maia MLS, Camacho L. Surveillance of adverse events following immunization in the late 2010s: an overview of the importance, tools, and challenges. Cad Saude Publica. 2020;36(Suppl 2):e00182019. doi:10.1590/0102-311x00182019.
   Google Scholar
• Nabavi M, Jandaghi J, Ghorbani R, Khaleghi Hashemian M, Shojaee H, Maherbonabi S, Mohammadzade F, Ghadamyari M, Bayat S, Faraji Z. The incidence of complications of vaccination in children and infants of Semnan, Iran. Koomesh. 2010;11:245–54.
   Google Scholar
• Sharafi R, Mortazavi J, Heidarzadeh A. Comparison of complications of pentavalent and DTP vaccination in infants aged 2–6 months in Anzali, Iran. Iran J Neonatology IJN. 2016;7:1–6.
   Google Scholar
• Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid Hexavalent vaccine in Indian infants. Indian Pediatr. 2017;54(1):15–20. doi:10.1007/s13312-017-0989-2.
   PubMed Web of Science ®Google Scholar
• Reynolds DL, Vidor E. Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience. Expert Rev Vaccines. 2014;13:943–68. doi:10.1586/14760584.2014.933674.
   PubMed Web of Science ®Google Scholar
• Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis. 2007;11(6):488–95. doi:10.1016/j.ijid.2007.01.006.
   PubMed Web of Science ®Google Scholar
• Dagan R, Igbaria K, Piglansky L, Melamed R, Willems P, Grossi A, Kaufhold A. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J. 1997;16:1113–21. doi:10.1097/00006454-199712000-00004.
   PubMed Web of Science ®Google Scholar